



ACE2-GFP Human Pulmonary Small Airway Epithelial Cells (HPuSAEPCs-ACE2-GFP)

Catalog #: HPEC002

Cell #: >5x10⁵ cells

Storage: Liquid Nitrogen until ready for culture.
While Culturing keep in 37°C CO₂ incubator

Product Format: Frozen Vial

GENERAL INFORMATION

Human Pulmonary Small Airway Epithelial Cells were isolated from normal human lung small airway. ACE2-GFP Expressing Human Pulmonary Small Airway Epithelial Cells were selected from puromycin resistant HPuSAEPCs after infected with lentiviruses expressing ACE2-GFP and the cells are shipped in frozen vials (provided @ passage 1). Human Epithelial Cell Medium (ECM001) is recommended for cell culture and these cells have a minimum average population doubling levels > 8 when cultured following the detailed protocol described below.

Product is for Research use only.

Frozen Vials are shipped in a Dry Ice Package.

CHARACTERIZATION OF THE CELLS

1. Pan-Cytokeratin Positive
2. E-7 negative
3. Typical cobblestone monolayer morphology in culture
4. HPuSAEPCs are negative for HIV-1, HBV, HCV, and mycoplasma

HANDLING OF ARRIVING CELLS

When you receive the dry ice package with cells in frozen vials, transfer the frozen vials of cells into a -80°C freezer for short period storage or a liquid nitrogen tank for long-term storage.

PROTOCOL FOR THAWING THE CELLS AND SUBCULTURE

1. Pre-coating of T25 flasks- Add 2ml each Alphabiocoat Solution (AC001) into a T25 flask to cover the whole surface of the flask, 30 mins later, remove excessive coating solution by aspiration. Rinse with 1xPBS and flask is ready to be used.
2. Thaw the frozen cell vial in a 37°C water bath first, and then transfer the cells into the pre-coated T25 flask with 10ml of Human Epithelial Cell Medium (ECM001), cells usually become confluent with 1-2 days and ready to be passaged.

FOR RESEARCH USE ONLY

NEUROMICS REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. v1-09809

www.neuromics.com

Neuromics Antibodies • 5325 West 74th Street, Suite 8 • Edina, MN 55439
phone 866-350-1500 • fax 612-677-3976 • e-mail pshuster@neuromics.com

3. To passage the cells, rinse the cells in a T25 flask with 5 ml HBSS (RT) twice; then add 2 ml Universal Detachment Solution (RT) (AD002) into one T25 flask; gently dispose the excessive Universal Detachment Solution within 20 seconds by aspiration.
4. Leave the T25 flask with the cells at RT or 37°C for 1 min. (Most cells usually will detach from the surface within 1-2 mins.) Otherwise, monitor the cells under a microscope until most of cells become rounded up, and then gently tap the flask against the bench surface, and the cells will move on the surface of the flask.
5. Add 5 ml Universal Neutralization Buffer (NB001) and spin down the cells with 800g centrifugation for 5 mins.
6. Re-suspend the cell pellet with 10 or 15 ml medium and transfer 5 ml each into 2 or 3 pre-coated T25 flasks (for 1/2 to 1/3 subculture ratio).
7. Change medium every 2 or 3 days and the cells usually become confluent within 7 days (when split at a 1/3 ratio).
8. To prepare quiescent cells, when cells are nearly confluent, replace with Human Epithelial Basal Cell Medium (ECM002) containing 0.5%FBS for about 8-12hrs.

FOR RESEARCH USE ONLY

NEUROMICS REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. v1-09809

www.neuromics.com

Neuromics Antibodies • 5325 West 74th Street, Suite 8 • Edina, MN 55439
phone 866-350-1500 • fax 612-677-3976 • e-mail pshuster@neuromics.com